IGF2BP1 and lung carcinoma: Consistent with these results, lung carcinoma patients expressing elevated Igf2bp1 levels along with mutant Kras have a strikingly reduced expected survival as compared to those patients with low levels of Igf2bp1 (15.45 months as opposed to 88.17 months, respectively, with a hazard ratio of 4.753).